Tuberculosis of the Central Nervous System

Joseph R. Zunt, MD, MPH Neuroinfectious Disease p. 1422-1438 October 2018, Vol.24, No.5 doi: 10.1212/CON.0000000000000648
REVIEW ARTICLES
BROWSE ARTICLES
Article as PDF
Article Level Metrics
-- Select an option --

PURPOSE OF REVIEW: This article details the epidemiology and clinical manifestations of central nervous system (CNS) tuberculosis (TB), provides guidance for diagnostic imaging and CSF testing, and recommends treatment strategies for tuberculous meningitis and other forms of CNS TB, illustrating key aspects of diagnosis and management with case presentations.

RECENT FINDINGS: Although improvements in our understanding of the pathogenesis and management of CNS TB have occurred over the past 50 years, the emergence of multidrug-resistant and extensively drug-resistant TB, the advent of acquired immunodeficiency syndrome (AIDS), and the subsequent availability of highly active antiretroviral therapy that can produce the immune reconstitution inflammatory syndrome have complicated the diagnosis and treatment of CNS TB. Advances in diagnostic assays promise to increase the speed of diagnosis as well as the percentage of people with a confirmed rather than a presumptive diagnosis. Advances in precision medicine have identified polymorphisms in the LTA4H gene that influence the risk for inflammation in patients with tuberculous meningitis.

SUMMARY: CNS TB continues to be a major cause of morbidity and mortality, with the majority of people affected living in low-income and middle-income countries. Newer diagnostic assays promise to increase the speed of diagnosis and improve appropriate selection of antituberculous therapy and anti-inflammatory medications. Despite these advances, CNS TB remains difficult to diagnose, and clinicians should have a low threshold for initiating empiric therapy in patients with presumptive infection.

Address correspondence to Dr Joseph R. Zunt, Harborview Medical Center, 325 Ninth Ave, Box 359775, Seattle, WA 98104, jzunt@uw.edu.

RELATIONSHIP DISCLOSURE: Dr Zunt receives research/grant support from the National Institutes of Health (2D43 TW009345-06, 1D43TW009137-01A1, 1D43TW009375-01A1, 1D43TW009763-01).

UNLABELED USE OF PRODUCTS/INVESTIGATIONAL USE DISCLOSURE: Dr Zunt reports no disclosure.

CONTINUUM AUDIO INTERVIEW AVAILABLE ONLINE

© 2018 American Academy of Neurology